Amlodipine/benazepril

Amlodipine/benazepril
Combination of
Amlodipine Calcium channel blocker
Benazepril ACE inhibitor
Clinical data
Pregnancy
category
  • US: D (Evidence of risk)
    Routes of
    administration    		 Oral
    ATC code
    • None
    Legal status
    Legal status
    Identifiers
    CAS Number
    PubChem CID
    ChemSpider
     ☒N☑Y (what is this?)  (verify)

    Amlodipine/benazepril, marketed in the U.S. as Lotrel by Novartis and manufactured as a generic drug by Teva and Sandoz, is an antihypertensive medication which combines a calcium channel blocker (amlodipine besilate) with an angiotensin converting enzyme inhibitor (benazepril).[1] This drug, like similar combinations, is prescribed when either agent alone is not sufficient to bring a person's blood pressure down to target range. As a combination agent, Lotrel shares the adverse reaction profile of both of its individual parts.[2][3]

    See also

    References

    1. ↑ Faulkner, Michele A; Hilleman, Daniel E (2005). "Amlodipine/benazepril: fixed dose combination therapy for hypertension". Expert Opinion on Pharmacotherapy. 2 (1): 165–178. doi:10.1517/14656566.2.1.165. ISSN 1465-6566.
    2. ↑ Drugs.com: Lotrel
    3. ↑ RxList.com: Lotrel


    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.